GlassScriptPhysician profile
Wesley S Nickens
NPI 1043405913
$4,017.66
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $88.59 · 2021: $521 · 2022: $1,845 · 2023: $1,423 · 2024: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,563.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $453.50 | 2021-2023 | |
| Glaxosmithkline, LLC. | $393.29 | 2021-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbott Laboratories | $340.51 | 2021-2024 | Freestyle Libre 3, Proclaim |
| Janssen Pharmaceuticals, INC | $338.07 | 2021-2023 | Xarelto, Spravato |
| Novo Nordisk INC | $301.49 | 2021-2023 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $277.21 | 2022-2023 | |
| Axsome Therapeutics, INC. | $224.12 | 2023 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $200.28 | 2022-2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $181.99 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $168.84 | 2022 | |
| Lilly USA, LLC | $122.13 | 2021-2023 | Mounjaro |
| Pfizer INC. | $121.36 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.67 | 2021-2023 | Trulance, Xifaxan |
| Nestle Healthcare Nutrition INC. | $81.05 | 2022-2023 | |
| Amgen INC. | $75.19 | 2021-2023 | Evenity, Prolia |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $66.46 | 2021-2022 | |
| Antares Pharma, INC. | $61.51 | 2021-2023 | Nocdurna, Xyosted, Tlando |
| Kyowa Kirin, INC. | $55.17 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $53.13 | 2022-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $48.23 | 2022-2023 | |
| Arbor Pharmaceuticals, INC. | $47.11 | 2020-2021 | |
| Lundbeck LLC | $44.24 | 2022-2023 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.34 | 2022-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $37.07 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $32.51 | 2021 | |
| Inspire Medical Systems, INC. | $31.29 | 2024 | Inspire |
| Kowa Pharmaceuticals America, INC. | $16.53 | 2023 | Seglentis, Livalo |
| Horizon Therapeutics Plc | $15.79 | 2022 | |
| Xeris Pharmaceuticals, INC. | $15.78 | 2023 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $14.84 | 2022 | |
| Philips North America LLC | $14.47 | 2023 | |
| Optinose US, INC. | $13.34 | 2021 | |
| Merck Sharp & Dohme LLC | $13.20 | 2021 | |
| Idorsia Pharmaceuticals US INC | $12.70 | 2023 | Quviviq |
| Inogen, INC. | $12.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Nickens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.